{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:29:24Z","timestamp":1794324564119,"version":"4.9.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T00:00:00Z","timestamp":1737763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The clinical manifestations and course of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) exhibits considerable heterogeneity. In this study, we aimed to explore radiographic progression over a defined period, employing the Warrick score as a semi-quantitative measure in early RA-ILD, and to assess the associated risk factors for progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>RA-ILD patients underwent consecutive Warrick scoring based on initial high-resolution computed tomography (HRCT) at diagnosis and the first follow-up. Associations between Warrick scores, pulmonary function tests, and patient characteristics were analyzed. The ROC curve assessed the predictive performance of the Warrick score change rate for ILD progression, while multivariable logistic regression analysis identified risk factors for progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Significant correlations were found between Warrick scores and age at RA-ILD diagnosis, age at ILD diagnosis, and baseline DAS28-ESR. For the severity score, correlations were <jats:italic>r<\/jats:italic>\u2009=\u20090.359, <jats:italic>r<\/jats:italic>\u2009=\u20090.372, and <jats:italic>r<\/jats:italic>\u2009=\u20090.298 (<jats:italic>p<\/jats:italic>\u2009=\u20090.001, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>p<\/jats:italic>\u2009=\u20090.014, respectively); for the extent score, <jats:italic>r<\/jats:italic>\u2009=\u20090.364, <jats:italic>r<\/jats:italic>\u2009=\u20090.318, and <jats:italic>r<\/jats:italic>\u2009=\u20090.255 (<jats:italic>p<\/jats:italic>\u2009=\u20090.001, <jats:italic>p<\/jats:italic>\u2009=\u20090.005, <jats:italic>p<\/jats:italic>\u2009=\u20090.038, respectively); and for the total score, <jats:italic>r<\/jats:italic>\u2009=\u20090.376, <jats:italic>r<\/jats:italic>\u2009=\u20090.367, and <jats:italic>r<\/jats:italic>\u2009=\u20090.280 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>p<\/jats:italic>\u2009=\u20090.001, <jats:italic>p<\/jats:italic>\u2009=\u20090.022, respectively). Annual changes in severity, extent, and total Warrick scores showed sensitivities of 91\u201397% and specificities of 98% for predicting progression over a 5-year follow-up. Cut-off values were 0.0278 for the severity score (AUC 0.954), 0.0227 for extent score (AUC 0.976), and 0.0694 for total score (AUC 0.946). Warrick severity, extent, and total scores increased significantly during follow-up. Age\u2009&gt;\u200950 years (OR 7.7; <jats:italic>p<\/jats:italic>\u2009=\u20090.028) and baseline usual interstitial pneumonia (UIP) pattern (OR 3.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.041) were identified as risk factors for progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Advanced age and UIP pattern were significant risk factors for progression. Warrick scoring may may help predict progression in RA-ILD, particularly through changes in severity, extent, and total scores. Due to the retrospective design and small sample size, further prospective studies with larger cohorts are needed to confirm these findings and validate Warrick scoring as a reliable marker for RA-ILD progression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s42358-025-00435-w","type":"journal-article","created":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T08:16:06Z","timestamp":1737792966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Warrick score in rheumatoid-arthritis interstitial lung disease: a promising tool for assessing the extent and progression of lung involvement"],"prefix":"10.1186","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5891-2032","authenticated-orcid":false,"given":"Duygu Temiz","family":"Karadag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevtap","family":"Dogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neslihan","family":"Gokcen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oznur Sadioglu","family":"Cagdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayten","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Cefle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"435_CR1","unstructured":"T Perez 1 MRJBC. Airways involvement in rheumatoid arthritis: clinical, functional, and HRCT findings - PubMed [Internet]. [cited 2023 Dec 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9603152\/"},{"key":"435_CR2","doi-asserted-by":"crossref","unstructured":"Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev [Internet]. 2021 [cited 2023 Dec 31];30(160). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34168062\/","DOI":"10.1183\/16000617.0011-2021"},{"key":"435_CR3","doi-asserted-by":"crossref","unstructured":"Alunno A, Gerli R, Giacomelli R, Carubbi F. Clinical, Epidemiological, and Histopathological Features of Respiratory Involvement in Rheumatoid Arthritis. Biomed Res Int [Internet]. 2017 [cited 2023 Dec 31];2017. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29238722\/","DOI":"10.1155\/2017\/7915340"},{"key":"435_CR4","doi-asserted-by":"crossref","unstructured":"Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics\u2013a large multicentre UK study. Rheumatology (Oxford) [Internet]. 2014 [cited 2023 Dec 31];53(9):1676\u201382. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24758887\/","DOI":"10.1093\/rheumatology\/keu165"},{"key":"435_CR5","doi-asserted-by":"crossref","unstructured":"Avouac J, Amrouche F, Meune C, Rey G, Kahan A, Allanore Y. Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. Semin Arthritis Rheum [Internet]. 2017 Apr 1 [cited 2023 Dec 31];46(5):537\u201343. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27908535\/","DOI":"10.1016\/j.semarthrit.2016.10.007"},{"key":"435_CR6","doi-asserted-by":"crossref","unstructured":"Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers [Internet]. 2018 Feb 8 [cited 2023 Dec 31];4. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29417936\/","DOI":"10.1038\/nrdp.2018.1"},{"key":"435_CR7","doi-asserted-by":"crossref","unstructured":"Esposito AJ, Chu SG, Madan R, Doyle TJ, Dellaripa PF. Thoracic Manifestations of Rheumatoid Arthritis. Clin Chest Med [Internet]. 2019 Sep 1 [cited 2023 Dec 31];40(3):545\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31376890\/","DOI":"10.1016\/j.ccm.2019.05.003"},{"key":"435_CR8","doi-asserted-by":"crossref","unstructured":"Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J [Internet]. 2010 Jun [cited 2023 Dec 31];35(6):1322\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19996193\/","DOI":"10.1183\/09031936.00092309"},{"key":"435_CR9","doi-asserted-by":"crossref","unstructured":"Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med [Internet]. 2011 Feb 1 [cited 2024 Sep 3];183(3):372\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20851924\/","DOI":"10.1164\/rccm.201004-0622OC"},{"key":"435_CR10","doi-asserted-by":"crossref","unstructured":"Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum [Internet]. 2010 Jun [cited 2023 Dec 31];62(6):1583\u201391. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20155830\/","DOI":"10.1002\/art.27405"},{"key":"435_CR11","doi-asserted-by":"crossref","unstructured":"Hyldgaard C, Hilberg O, Pedersen AB, Ulrichsen SP, L\u00f8kke A, Bendstrup E, et al. A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis [Internet]. 2017 [cited 2023 Dec 31];76(10):1700\u20136. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28611082\/","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"435_CR12","doi-asserted-by":"crossref","unstructured":"Hyldgaard C, Ellingsen T, Hilberg O, Bendstrup E. Rheumatoid arthritis-associated interstitial lung disease: clinical characteristics and predictors of mortality. Respiration [Internet]. 2019 Nov 1 [cited 2023 Dec 31];98(5):455\u201360. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31597131\/","DOI":"10.1159\/000502551"},{"key":"435_CR13","doi-asserted-by":"crossref","unstructured":"Kelly CA, Nisar M, Arthanari S, Carty S, Woodhead FA, Price-Forbes A, et al. Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study. Rheumatology (Oxford) [Internet]. 2021 Apr 1 [cited 2023 Dec 31];60(4):1882\u201390. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33150434\/","DOI":"10.1093\/rheumatology\/keaa577"},{"key":"435_CR14","unstructured":"Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford) [Internet]. 2021 Aug 1 [cited 2023 Dec 31];60(8):3689\u201398. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33462611\/"},{"key":"435_CR15","unstructured":"Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford) [Internet]. 2017 Mar 1 [cited 2023 Dec 31];56(3):344\u201350. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27940586\/"},{"key":"435_CR16","doi-asserted-by":"crossref","unstructured":"Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Progressive decline of lung function in rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol [Internet]. 2017 Mar 1 [cited 2023 Dec 31];69(3):542\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27788297\/","DOI":"10.1002\/art.39971"},{"key":"435_CR17","doi-asserted-by":"crossref","unstructured":"Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J [Internet]. 2016 Feb 1 [cited 2023 Dec 31];47(2):588\u201396. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26585429\/","DOI":"10.1183\/13993003.00357-2015"},{"key":"435_CR18","doi-asserted-by":"crossref","unstructured":"Jacob J, Bartholmai BJ, Rajagopalan S, Brun AL, Egashira R, Karwoski R, et al. Evaluation of computer-based computer tomography stratification against outcome models in connective tissue disease-related interstitial lung disease: a patient outcome study. BMC Med [Internet]. 2016 Nov 23 [cited 2023 Dec 31];14(1). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27876024\/","DOI":"10.1186\/s12916-016-0739-7"},{"key":"435_CR19","doi-asserted-by":"crossref","unstructured":"Crews MS, Bartholmai BJ, Adegunsoye A, Oldham JM, Montner SM, Karwoski RA, et al. Automated CT Analysis of Major Forms of Interstitial Lung Disease. J Clin Med [Internet]. 2020 Nov 1 [cited 2023 Dec 31];9(11):1\u201311. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33238466\/","DOI":"10.3390\/jcm9113776"},{"key":"435_CR20","doi-asserted-by":"crossref","unstructured":"Makol A, Nagaraja V, Amadi C, Pugashetti JV, Caoili E, Khanna D. Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol [Internet]. 2023 [cited 2024 May 7];19(6):613\u201326. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36999788\/","DOI":"10.1080\/1744666X.2023.2198212"},{"key":"435_CR21","unstructured":"Warrick JH, Bhalla M, Schabel SI, Silver RM. High resolution computed tomography in early scleroderma lung disease - PubMed [Internet]. 1991 [cited 2024 Jan 1]. pp. 1520\u20138. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/1765976\/"},{"key":"435_CR22","doi-asserted-by":"crossref","unstructured":"Salaffi F, Carotti M, Tardella M, Di Carlo M, Fraticelli P, Fischetti C, et al. Computed tomography assessment of evolution of interstitial lung disease in systemic sclerosis: Comparison of two scoring systems. Eur J Intern Med [Internet]. 2020 Jun 1 [cited 2024 Jan 1];76:71\u20135. Available from: http:\/\/www.ejinme.com\/article\/S0953620520300522\/fulltext","DOI":"10.1016\/j.ejim.2020.02.009"},{"key":"435_CR23","doi-asserted-by":"crossref","unstructured":"Kur-Zalewska J, Kisiel B, Kania-Pud\u0142o M, T\u0142ustochowicz M, Chcia\u0142owski A, T\u0142ustochowicz W. A dose-dependent beneficial effect of methotrexate on the risk of interstitial lung disease in rheumatoid arthritis patients. PLoS One [Internet]. 2021 Apr 1 [cited 2024 Jan 1];16(4). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33861812\/","DOI":"10.1371\/journal.pone.0250339"},{"key":"435_CR24","doi-asserted-by":"crossref","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum [Internet]. 2010 [cited 2024 Jan 1];62(9):2569\u201381. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20872595\/","DOI":"10.1002\/art.27584"},{"key":"435_CR25","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Antoniou KM, Bissell BD, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med [Internet]. 2022 May 1 [cited 2024 Jan 1];205(9):E18\u201347. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35486072\/"},{"key":"435_CR26","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med [Internet]. 2018 Sep 1 [cited 2024 Jan 1];198(5):e44\u201368. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30168753\/"},{"key":"435_CR27","doi-asserted-by":"crossref","unstructured":"Bellia M, Cannizzaro F, Scichilone N, Riili M, Triolo G, Midiri M, et al. HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities. Radiol Med [Internet]. 2009 Mar [cited 2024 Sep 4];114(2):190\u2013203. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19266260\/","DOI":"10.1007\/s11547-009-0367-9"},{"key":"435_CR28","doi-asserted-by":"crossref","unstructured":"Yilmazer B, G\u00fcm\u00fc\u015fta\u015f S, Co\u015fan F, \u0130nan N, Ensaro\u011flu F, Erba\u011f G, et al. High-resolution computed tomography and rheumatoid arthritis: semi-quantitative evaluation of lung damage and its correlation with clinical and functional abnormalities. Radiol Med [Internet]. 2016 Mar 1 [cited 2024 Jan 26];121(3):181\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26493688\/","DOI":"10.1007\/s11547-015-0590-5"},{"key":"435_CR29","doi-asserted-by":"crossref","unstructured":"Joy GM, Arbiv OA, Wong CK, Lok SD, Adderley NA, Dobosz KM, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis. Eur Respir Rev [Internet]. 2023 Mar 1 [cited 2024 Jan 27];32(167). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36889782\/","DOI":"10.1183\/16000617.0210-2022"},{"key":"435_CR30","doi-asserted-by":"crossref","unstructured":"Koduri G, Solomon JJ. Identification, monitoring, and management of Rheumatoid Arthritis\u2013Associated interstitial lung disease. Arthritis and rheumatology. John Wiley and Sons Inc; 2023.","DOI":"10.1002\/art.42640"},{"key":"435_CR31","unstructured":"Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med [Internet]. 2021 May 1 [cited 2024 May 11];9(5):476\u201386. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33798455\/"},{"key":"435_CR32","unstructured":"Solomon JJ, Danoff SK, Woodhead FA, Hurwitz S, Maurer R, Glaspole I, et al. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respir Med [Internet]. 2023 Jan 1 [cited 2024 May 11];11(1):87\u201396. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36075242\/"},{"key":"435_CR33","doi-asserted-by":"crossref","unstructured":"Raghu G, Ghazipura M, Montesi SB, Silver RM, Hossain T, Macrea M, et al. Treatment of Systemic Sclerosis-associated Interstitial Lung Disease: Evidence-based Recommendations. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med [Internet]. 2024 Jan 15 [cited 2024 Mar 31];209(2):137\u201352. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37772985\/","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"435_CR34","doi-asserted-by":"crossref","unstructured":"Chai D, Sun D, Wang Y, Song Y, Wu N, Ye Q. Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease. Front Med (Lausanne) [Internet]. 2023 [cited 2024 Jan 26];10. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37809328\/","DOI":"10.3389\/fmed.2023.1265355"},{"key":"435_CR35","doi-asserted-by":"crossref","unstructured":"Lee H, Lee S, Il, Kim HO. Recent Advances in Basic and Clinical Aspects of Rheumatoid Arthritis-associated Interstitial Lung Diseases. Journal of rheumatic diseases [Internet]. 2022 [cited 2024 Jan 28];29(2):61\u201370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37475899\/","DOI":"10.4078\/jrd.2022.29.2.61"},{"key":"435_CR36","doi-asserted-by":"crossref","unstructured":"Chen N, Diao CY, Gao J, Zhao DB. Risk factors for the progression of rheumatoid arthritis-related interstitial lung disease: Clinical features, biomarkers, and treatment options. Semin Arthritis Rheum [Internet]. 2022 Aug 1 [cited 2024 Jan 26];55. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35472663\/","DOI":"10.1016\/j.semarthrit.2022.152004"},{"key":"435_CR37","doi-asserted-by":"crossref","unstructured":"Liu L, Fang C, Sun B, Bao R, Zhang H. Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: A single-center retrospective study from China. Int J Rheum Dis [Internet]. 2022 Jul 1 [cited 2024 Jan 26];25(7):795\u2013802. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35633522\/","DOI":"10.1111\/1756-185X.14351"},{"key":"435_CR38","doi-asserted-by":"crossref","unstructured":"Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open [Internet]. 2013 [cited 2024 Jan 26];3(9). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24038004\/","DOI":"10.1136\/bmjopen-2013-003132"},{"key":"435_CR39","doi-asserted-by":"crossref","unstructured":"Liu L, Fang C, Sun B, Bao R, Zhang H. Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: A single-center retrospective study from China. Int J Rheum Dis [Internet]. 2022 Jul 1 [cited 2024 Sep 4];25(7):795\u2013802. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35633522\/","DOI":"10.1111\/1756-185X.14351"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00435-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00435-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00435-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T08:16:27Z","timestamp":1737792987000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-025-00435-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,25]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["435"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00435-w","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,25]]},"assertion":[{"value":"15 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the Declaration of Helsinki and was approved by the Kocaeli University Faculty of Medicine Ethics Committee KOU\/GOKAEK, Kocaeli, Turkey), with project number 2024\/48.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}